Ex vivo sentinel lymph node mapping in colorectal cancer using [۹۹mTc]Tc-HMPAO-patent blue liposomes: A hybrid radiotracer/dye approach

Introduction: To assess the effectiveness of [۹۹mTc]Tc-HMPAO-Patent blue liposomes for sentinel lymph node (SLN) mapping in colorectal cancer (CRC) using combined visual and radiotracer detection in a single injection.Methods: In this prospective study, ۴۰ CRC patients underwent surgical resection. Post-resection, PEGylated or non-PEGylated [۹۹mTc]Tc-HMPAO liposomes were injected peritumorally ex vivo. SLNs were identified by blue dye visualization and gamma probe detection, followed by pathological assessment.Results: SLNs were not detected in ۶ patients (۱۵%). Among the ۳۴ cases with SLN detection, ۵ (۱۴.۷%) had metastatic involvement. In ۲ cases with negative SLNs, non-sentinel nodes were positive, leading to pathological upstaging in ۲ patients (۵%). The overall detection rate was ۸۵%, with sensitivities of ۸۰% for colon and ۵۰% for rectal cancer. The false-negative rate was ۲۸%.Conclusion: [۹۹mTc]Tc-HMPAO-Patent blue liposomes offer an effective dual-modality approach for SLN mapping in CRC, enhancing staging accuracy, especially in colon cancer.

کلیدواژه ها:

Sentinel lymph node ، Colorectal cancer ، Lymphoscintigraphy ، Nano liposome ، [۹۹mTc]Tc-HMPAO ، Patent blue